Results 91 to 100 of about 326,443 (336)

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab

Biomolecules, 2019
G309 or S310 mutations on the HER2 extracellular domain II induce receptor activation. Clinically, S310F is most frequent among HER2 extracellular domain mutations and patients with the S310F mutation without HER2 amplification responded to trastuzumab ...
Jung Won Shin, Soohyun Kim, Suji Ha, Byungsan Choi, Seongyeong Kim, Seock-Ah Im, Tae-Young Yoon, Junho Chung   +7 more
doaj   +1 more source

Implications of subcutaneous or intravenous delivery of trastuzumab: further insight from patient interviews in the PrefHer study [PDF]

, 2015
BACKGROUND: The 2 Cohort randomised PrefHer trial examined the preferences of HER2+ve primary breast cancer patients for intravenous (IV) or subcutaneous (SC) delivery of trastuzumab via a Single Injectable Device (SID) or hand-held syringe (HHS).
Basch, C. Langridge, Ismael, J. Kilkerr, K. Monson, L. Fallowfield, Melichar, Piccart-Gebhart, Pivot, Pivot, S. Osborne, Samanta, Slamon, Stoner, V. Jenkins   +14 more
core   +1 more source

Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation

Advanced Science, EarlyView.
Oxidative phosphorylation (OXPHOS) activity serves as a critical metabolic determinant of radiotherapy outcomes in esophageal squamous cell carcinoma (ESCC). The CEBPB/AREG/EREG axis drives radioresistance in ESCC by reprogramming OXPHOS. AREG and EREG function as predictive biomarkers for nCRT response and prognosis of ESCC patients.
Zhang Lin, Meilian Yao, Xin Xu, Dong Zhang, Lei Xu, Ling Rong, Xiaohang Wang, Yi Duan, Chengkun Chen, Jun Gu, Yao Zhang, Qiang Liu, Qing Ye, Gaoping Cui, Yujun Hao, Xiumei Ma   +15 more
wiley   +1 more source

Enzymatic Remodelling of Tumour Microenvironment Enhances Anti‐CEACAM5 CAR T‐Cell Efficacy Against Colorectal Cancer

Advanced Science, EarlyView.
This study shows anti‐CEACAM5 CAR T‐cells are ineffective against colorectal cancer (CRC) because of CEACAM5 sequestration at intercellular junctions and the thick tumour cell glycocalyx. Enzymatic treatments of CRC cell monolayer/tissue section with trypsin or hyaluronidase restore CEACAM5 availability, enhance CAR T‐cell activation, increase ...
Debasis Banik, Christopher J. Ward, Soura Chakraborty, Ziwei Zhang, Daniel Heraghty, Prasanna Suresh, Bing Li, Shekhar Kedia, Jhuma Pramanik, Simon J. Davis, James P. Roy, Michael A. Chapman, Bidesh Mahata, David Klenerman   +13 more
wiley   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

PLA2G16‐Mediated Tetracosatetraenoic Acid Rewires Fatty Acid Oxidation to Impair CD8+ T Cell Immune Function in Promoting Breast Cancer Lung Metastasis

Advanced Science, EarlyView.
Illustrating how tumor‐derived PLA2G16 regulates tetracosatetraenoic acid (C24:4 (n‐6)) accumulation and CD8+ T cell activation via the C24:4‐PPARα‐FAO axis in early metastatic niches, thereby promoting lung metastasis of triple‐negative breast cancer.
Yubi Gan, Die Meng, Lei Lang, Jing Luo, Peijin Dai, Chao Chang, Zexiu Lu, Yuetong Guo, Rui Wang, Shanchun Chen, Xi Tang, Yixuan Hou, Dongmei Tan, Manran Liu   +13 more
wiley   +1 more source

Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data

Breast Cancer: Targets and Therapy, 2020
Patrick M Dillon,1 Christiana M Brenin,1 Craig L Slingluff Jr2 1University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA; 2University of Virginia, Department of Surgery, Charlottesville, VA 22908, USACorrespondence: Patrick
Dillon PM, Brenin CM, Slingluff CL Jr
doaj  

Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30 [PDF]

, 2019
BACKGROUND: The benefits of chemotherapy in node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with the 21-gene recurrence score (RS) of 18-30, particularly those with RS 26-30 ...
Cho, Young Up, Colditz, Graham A, Han, Yunan, Kim, Seung Il, Liu, Ying, Park, Byeong-Woo, Park, Seho, Park, Yikyung, Peterson, Lindsay L, Toriola, Adetunji T   +9 more
core   +1 more source

HER2 testing in breast cancer: Opportunities and challenges [PDF]

, 2006
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Annette Lebeau, Arnould L, Baselga J, Bast, Bilous M, Carter P, Cho HS, Clynes RA, Cobleigh MA, Connor CS, Crowder RJ, Dandachi N, De Laurentiis M, Di Leo A, Di Loreto C, Goldhirsch A, Gschwind A, Hancock MC, Hanna W, Harari D, Hortobagyi GN, Hudziak RM, Jacobs TW, Kobayashi M, Lebeau A, Lohrisch C, Mass R, Mass R, Molina MA, Mueller-Holzner E, Nagata Y, Osborne CK, Paik S, Piccart MJ, Piccart-Gebhart MJ, Pietras RJ, Pinto AE, Revillion F, Romond EP, Ross JS, Seidman AD, Sliwkowski MX, Tanner M, Taucher S, Yakes FM, Yarden Y   +45 more
core   +1 more source

Precise Regulation of Membrane Proteins: From Physical Technology to Biomolecular Strategy

Advanced Science, EarlyView.
This review summarizes the emerging strategies for the precise regulation of membrane proteins using physical stimuli and biomolecule‐based tools. These methods provide new insights into cell regulation and offer promising directions for future disease treatment.
Xiu Zhao, Qingqing Zhou, Mengli Li, Wen Zou, Zhenzhong Zhang, Jinjin Shi, Junjie Liu   +6 more
wiley   +1 more source